A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Response to a Single Treatment With Oral MK0974 [telcagepant] With Placebo and Comparator in Subjects With Moderate to Severe Acute Migraine With or Without Aura
Phase of Trial: Phase III
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Telcagepant (Primary) ; Zolmitriptan
- Indications Migraine
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 27 Jun 2008 Results presented at American Headache Society annual meeting 2008.
- 23 Oct 2007 Status changed from in progress to completed.
- 17 Aug 2007 Status changed from recruiting to in progress.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History